Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies
Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S153300282600085X?dgcid=rss_sd_all
Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S153300282600085X?dgcid=rss_sd_all
“Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies.” Clinical Colorectal Cancer.
@article{article99908,
title = {Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S153300282600085X?dgcid=rss_sd_all}
}